ASBMR: Romosozumab Linked to Reduced Fracture Risk

This article originally appeared here.
Share this content:
ASBMR: Romosozumab Linked to Reduced Fracture Risk
ASBMR: Romosozumab Linked to Reduced Fracture Risk

MONDAY, Sept. 19, 2016 (HealthDay News) -- For postmenopausal women with osteoporosis, romosozumab is associated with reduced risk of vertebral fracture at 12 months, according to a study published online Sept. 18 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society for Bone and Mineral Research, held from Sept. 16 to 19 in Atlanta.

Felicia Cosman, M.D., from the Regional Bone Center at Helen Hayes Hospital in West Haverstraw, N.Y., and colleagues randomized 7,180 postmenopausal women with a T score of −2.5 to −3.5 at the total hip or femoral neck to subcutaneous injections of romosozumab or placebo monthly for 12 months. Thereafter, patients in each group received denosumab for 12 months administered subcutaneously every six months.

The researchers found that 0.5 percent of patients in the romosozumab group and 1.8 percent in the placebo group had new vertebral fractures at 12 months (P < 0.001). Clinical fractures occurred in 1.6 and 2.5 percent of patients in the romosozumab and placebo groups, respectively (P = 0.008). No significant between-group difference was seen in the risk of non-vertebral fractures (P = 0.10). After each group made the transition to denosumab, at 24 months, the rates of vertebral fractures were significantly lower in the romosozumab group (P < 0.001).

"In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months," the authors write.

The study was funded by Amgen and UCB Pharma, the manufacturers of romosozumab.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for &#126;25&#37; ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »